Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3079874 | 0.92 | SMN1; SMN2 (0.55) | SMN1; SMN2L3MBTL1TSHRLMNAMEN1 | |
| SCHEMBL8085947 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2L3MBTL1TSHRMEN1KMT2A | |
| SCHEMBL5533206 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2L3MBTL1TSHRHPGDLMNA | |
| SCHEMBL8473133 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1TSHRMAPK1HTR1A | |
| SCHEMBL3066643 | 0.84 | SMN1; SMN2 (0.62) | SMN1; SMN2L3MBTL1TSHRHPGDLMNA | |
| SCHEMBL6550190 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1TSHRNPC1MAPK1 | |
| SCHEMBL1053518 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2L3MBTL1TSHRLMNAMAPK1 | |
| SCHEMBL16953073 | 0.81 | KMT2A (0.51) | SMN1; SMN2L3MBTL1TSHRHPGDKMT2A | |
| SCHEMBL95873 | 0.81 | ALDH1A1 (0.53) | SMN1; SMN2L3MBTL1TSHRMEN1KMT2A | |
| SCHEMBL2806322 | 0.80 | L3MBTL1 (0.50) | SMN1; SMN2L3MBTL1TSHRHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | SMN1; SMN2 4291/4885L3MBTL1 4797/4885TSHR 3211/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | SMN1; SMN2 4291/4885L3MBTL1 4797/4885TSHR 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.